Latest news with #ZS
Yahoo
2 days ago
- Business
- Yahoo
ZS expands partnership with Salesforce to help companies scale AI agents with Agentforce
EVANSTON, Ill., June 25, 2025--(BUSINESS WIRE)--ZS announced the continued expansion of its partnership with Salesforce to offer consulting and implementation services for Agentforce, Salesforce's digital labor platform. With a focus on AI to help companies solve commercialization and go-to-market challenges, ZS helps clients implement and manage evolving workforces in which humans and AI agents complement each other to drive business value in sectors including pharma, healthcare, medtech, travel and retail. By using ZS's services for Agentforce, clients are able to deploy and scale AI agents with a trusted, open and complete agent platform. These AI agents help drive tangible business outcomes while helping to ensure governance and compliance are built in from day one. "Organizations need a new labor model that unlocks the full potential of humans with AI at work. ZS is a critical partner for identifying and developing specific use cases with our joint customers across industries, helping to ensure tailored and effective AI solutions for scaling digital labor," said Phil Samenuk, SVP of Global Alliances & Channels and Outsourcing Service Providers, Salesforce. "With Agentforce constantly evolving and expanding, ZS demonstrates the company's commitment to empowering customers to deliver success with Agentforce." ZS has been at the forefront of innovation with Agentforce and has developed solutions and services to help clients quickly get up and running across multiple industries, including: Pharma and healthcare: ZS and Salesforce are redefining pharma's commercialization and go-to-market strategies by embedding AI into engagement workflows for sales representatives, medical science liaisons, key account managers and patient case managers. This streamlines operations, prioritizes interventions and delivers real-time insights that improve both healthcare provider and patient experiences. Medtech: ZS's services for Agentforce help track opportunities, plan and log sales calls, manage accounts and generate insights. A real-world example: AI agents are helping medtech companies manage product warranties, coordinate returns and streamline field service operations, all of which accelerate product support efforts. Travel and retail: Clients can engage with ZS to use Agentforce to leverage lead scoring, sales development, sales coaching, contract automation and service insights in an effort to increase personalization and productivity across the customer journey. "ZS is committed to helping sales and marketing teams blend the human and digital touch to deliver growth and impact—and our Salesforce partnership is critical," said Swati Gokhale, ZS principal for strategic alliances and investments. "Agentforce opens up real opportunities for organizations to boost productivity, improve customer experiences and bring AI into day-to-day work in a meaningful way. With our deep industry knowledge and proven implementation expertise, we're helping clients move faster and smarter as they build and scale their digital workforce." "The real power of Agentforce lies in embedding AI agents into everyday workflows," added Srihari Sarangan, a ZS principal focused on digital transformation in pharma. "We're helping clients go beyond pilots to scale digital labor that augments real roles and drives measurable impact across the customer journey." Salesforce, Agentforce and others are among the trademarks of Salesforce, inc. About ZS ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 13,000 employees in over 35 offices worldwide. To learn more, visit or follow us on LinkedIn. View source version on Contacts MediaMaryam AyromlouRuder FinnZS-RFMedia@ 703-474-5685 Sign in to access your portfolio
Time of India
3 days ago
- Business
- Time of India
This Chhapra boy has built a global tech biz for life sciences
Prabha Sinha says his firm, ZS, works with 199 of the top 200 pharma companies in the world; his India centres have become central to the company, and host 10,000 of the 13,000 employees globally; a lot of the work now is around analytics & AI BENGALURU: The day before we spoke, Prabha Sinha had had litti and chokha for lunch, and some more Bihari cuisine for dinner at Potbelly restaurant in Bihar Niwas in Delhi. 'Couldn't resist it,' he says laughing. Prabha, founder of ZS – a US consulting and technology firm that works with 199 of the top 200 pharma companies in the world – was born in Chhapra in Bihar. His father was a lawyer, and they lived in a joint family with his uncle who had a farm. When it was time for school, Prabha was put in a boarding school in Patna, some 70 km away. But he loved visiting his village, loved running around barefoot there. Prabha did well in school, and got into IIT Kharagpur's mechanical engineering course. From there, like many IITians of the time, he moved to the US for a PhD. His advisor in the University of Massachusetts (UMass) was someone who was involved in both engineering and operations research, and so the PhD combined both aspects, and eventually Prabha found himself teaching quantitative methods in business schools – first at UMass, and then at Kellogg School of Management at Northwestern University. At Kellogg, he came across Andy Zoltners, a professor in marketing, and together they did some research on optimisation algorithms for sales forces. They then started applying the algorithms to issues like how large sales forces should be, how best to deploy sales forces geographically, how to optimise size and deployment simultaneously. This was the 1970s. A few companies with mainframes used the algorithms. But the big breakthrough came in 1981, when IBM popularised PCs. 'That allowed us to display answers directly to end-users and interact with them,' Prabha says. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Would you like to know more? Undo In 1983, they founded ZS, a combination of the first letter of their surnames. Initially, ZS worked with many industries, but the biggest traction came from life sciences. This persuaded them to focus on that industry. Today, they work across the life science spectrum, from drug discovery and development to commercialisation and patient engagement. India's central role India began to assume importance for ZS in the 2000s, when Prabha and Andy saw an opportunity in moving beyond IP-based consulting to also implement IT for clients. For one of the most regulated industries in the world, IT was becoming critical, and surely there was no better place for IT than India. That importance surged over the past decade, as analytics and AI became core to businesses. Today, India accounts for three-quarters of ZS' 13,000 employees worldwide, and they are involved in almost everything ZS does. ZS' biggest centres in India are in Pune and Gurugram. It also has centres in Bengaluru, Chennai and Noida. About 10,000 of its 13,000 employees are in India. The company has 385 shareholders. Of them, 13% are in India and 20% started life in India. ZS is becoming more Indian owned, founder Prabha Sinha says Analytics and AI is where ZS is increasingly focusing. Prabha says if there's a rare disease, ZS can help its pharma customers find potential patients for clinical studies by mining patient data in, say, the US. Mohit Sood , who leads the India operations and who has spent 18 years with ZS, says his teams developed a digital twin for a pharma company's supply chain. The system flags possible errors and hindrances in the supply chain much in advance. 'We've been able to improve their ability to match the demand and supply by more than 30%,' Mohit says. In the coming times, Mohit says, bringing far greater efficiencies would become critical as drug development focuses on niche diseases. These, he says, will bring in revenue of only about half a billion dollars, compared to traditional blockbuster drugs for mass diseases that yielded revenue of $3 bn to $6 bn. And there's fierce competition. That means costs of drug development, commercialisation, and patient engagement all have to drop sharply. 'Close to about 500 drug launches are planned from 2026 onwards. So there's going to be a lot of action,' Mohit says. India will be in the thick of it. Prabha was in Delhi because ZS decided to have its annual board meeting here. 'That gives you some insight about how important India has become for us,' he says. --------------------------------------- Prabha Sinha, Founder, ZS Our India team is now part of almost every project we do anywhere in the world. About three years ago, we launched an AI-powered analytics platform for organisations to run their sales and marketing functions. Most of the development and support of that is done in India. Some 150 companies today use it. If a salesperson in the US is going to visit a customer, AI agents advise him on what he should do with the customer, what offers he should make, what messages might resonate. The platform even advises them on which customers they should see. They are getting just-in-time advice. - Prabha Sinha, Founder, ZS Mohit Sood, Regional Managing Principal, ZS India The biggest thing that GenAI and classical AI are able to do together is to narrow down the set of molecules for drug discovery for the particular target you have. So, rather than going to wet labs, injecting it in the patient and seeing what happens, you're able to use AI and a ton of data to be able to conduct in silico experiments (computer simulations). This improves throughput dramatically. Another big impact of AI is in improving the operational efficiency of clinical trials. For any drug, you depend on 100 to 250 clinical sites for trials. The adherence to protocols across all these sites, documentation of all evidence, quality checks, and finally the ability to produce it to the US FDA or the European Agency, is not an easy task. With AI and GenAI, we'll be able to collect the data much more appropriately, identify data errors early on, ensure all data lineage. - Mohit Sood, Regional Managing Principal, ZS India AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Business Wire
3 days ago
- Business
- Business Wire
ZS expands partnership with Salesforce to help companies scale AI agents with Agentforce
EVANSTON, Ill.--(BUSINESS WIRE)--ZS announced the continued expansion of its partnership with Salesforce to offer consulting and implementation services for Agentforce, Salesforce's digital labor platform. With a focus on AI to help companies solve commercialization and go-to-market challenges, ZS helps clients implement and manage evolving workforces in which humans and AI agents complement each other to drive business value in sectors including pharma, healthcare, medtech, travel and retail. By using ZS's services for Agentforce, clients are able to deploy and scale AI agents with a trusted, open and complete agent platform. These AI agents help drive tangible business outcomes while helping to ensure governance and compliance are built in from day one. 'Organizations need a new labor model that unlocks the full potential of humans with AI at work. ZS is a critical partner for identifying and developing specific use cases with our joint customers across industries, helping to ensure tailored and effective AI solutions for scaling digital labor,' said Phil Samenuk, SVP of Global Alliances & Channels and Outsourcing Service Providers, Salesforce. 'With Agentforce constantly evolving and expanding, ZS demonstrates the company's commitment to empowering customers to deliver success with Agentforce.' ZS has been at the forefront of innovation with Agentforce and has developed solutions and services to help clients quickly get up and running across multiple industries, including: Pharma and healthcare: ZS and Salesforce are redefining pharma's commercialization and go-to-market strategies by embedding AI into engagement workflows for sales representatives, medical science liaisons, key account managers and patient case managers. This streamlines operations, prioritizes interventions and delivers real-time insights that improve both healthcare provider and patient experiences. Medtech: ZS's services for Agentforce help track opportunities, plan and log sales calls, manage accounts and generate insights. A real-world example: AI agents are helping medtech companies manage product warranties, coordinate returns and streamline field service operations, all of which accelerate product support efforts. Travel and retail: Clients can engage with ZS to use Agentforce to leverage lead scoring, sales development, sales coaching, contract automation and service insights in an effort to increase personalization and productivity across the customer journey. 'ZS is committed to helping sales and marketing teams blend the human and digital touch to deliver growth and impact—and our Salesforce partnership is critical,' said Swati Gokhale, ZS principal for strategic alliances and investments. 'Agentforce opens up real opportunities for organizations to boost productivity, improve customer experiences and bring AI into day-to-day work in a meaningful way. With our deep industry knowledge and proven implementation expertise, we're helping clients move faster and smarter as they build and scale their digital workforce.' 'The real power of Agentforce lies in embedding AI agents into everyday workflows,' added Srihari Sarangan, a ZS principal focused on digital transformation in pharma. 'We're helping clients go beyond pilots to scale digital labor that augments real roles and drives measurable impact across the customer journey.' Salesforce, Agentforce and others are among the trademarks of Salesforce, inc. About ZS ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 13,000 employees in over 35 offices worldwide. To learn more, visit or follow us on LinkedIn.
Yahoo
10-06-2025
- Business
- Yahoo
Zscaler Nears $3B ARR Goal: Can It Maintain the Momentum Through FY25?
Zscaler ZS ended third-quarter fiscal 2025 with $2.9 billion in annual recurring revenues (ARR), representing the third consecutive quarter of 23% year-over-year growth. The management stated that it remains confident in achieving its $3 billion ARR target by the end of the fourth quarter of fiscal key driver is the Z-Flex purchasing program launched during the third quarter, which simplifies procurement and allows customers to scale adoption of Zscaler's platform. Z-Flex generated $65 million in TCV bookings in its first quarter, with large clients like a Fortune 500 tech firm increasing their ARR by more than 40% to nearly $19 is also leaning heavily into three strategic pillars – Zero Trust Everywhere, Data Security Everywhere, and Agentic Operations (its artificial intelligence [AI]-driven initiative). Together, these areas now account for nearly $1 billion in standout here is Zero Trust Everywhere. Zscaler ended the third quarter with more than 210 enterprise customers in this segment, up 60% from the previous quarter. ZS intends to triple the customer base for this offering from 130 to over 390 by the end of fiscal 2026, and it's well on track to do just Zscaler ended the quarter with 642 customers generating more than $1 million in ARR and 3,363 customers with ARR over $100,000. Its 114% trailing 12-month net retention rate shows continued expansion within existing accounts. With a strong platform, disciplined execution, and growing demand for AI and Zero Trust capabilities, Zscaler appears well-positioned to drive the next phase of ARR growth. Competitors like CyberArk CYBR and SentinelOne S are also gaining ground through platform expansion and AI innovation. CyberArk ended its first quarter of fiscal 2025 with $1.215 billion in ARR, representing a year-over-year increase of 50%. The robust growth was driven by the sustained growth of subscriptions and increased adoption of CyberArk's identity security a small competitor, SentinelOne's ARR is also growing rapidly with reaching $948 million at the end of the first quarter of fiscal 2026. This represents a year-over-year rise of 24% fueled by growing adoption of SentinelOne's AI-first Singularity platform and Purple AI. Shares of Zscaler have surged 66.3% year to date compared with the Zacks Security industry's growth of 22%. Image Source: Zacks Investment Research From a valuation standpoint, ZS trades at a forward price-to-sales ratio of 15.21, slightly above the industry's 14.77. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Zscaler's fiscal 2026 earnings is pegged at $3.18 per share, up by 3.92% over the past 30 days, which implies a 0.31% drop year over year. The consensus mark for fiscal 2027 is also up by 2.01% over the past 30 days at $3.55 per share, indicating a year-over-year increase of 11.86%. Image Source: Zacks Investment Research ZS stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SentinelOne, Inc. (S) : Free Stock Analysis Report CyberArk Software Ltd. (CYBR) : Free Stock Analysis Report Zscaler, Inc. (ZS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Hypebeast
10-06-2025
- Automotive
- Hypebeast
MG Motor's Latest ZS SUV Model Arrives in the Middle East
MG Motorannounces the regional launch of its all-new ZS SUV model, bringing its latest developments in design and tech to theMiddle East. Having cut through the noise of the car market with its previous ZS generations, the latest arrival continues to build on the range's success by delivering a practical combination of space and enhanced performance. From the outside, the signature sculpted shape, hunter-eye style LED headlights, and 18-inch alloy wheels are maintained, while the addition of a spoiler gives the model a new sporty quality. With inner-city driving becoming a growing factor for those in the region, theSUVoffers a 1.5-liter engine with two powertrain options, including a 112 horsepower and 168 horsepower variant. Both of these options come with three drive modes that allow the car to adapt from tight city streets to open highways. Keeping safety at the forefront of the design approach, the brand updates the ZS with forward collision warning and speed assist as well as a 360° camera that shares visuals on a built-in infotainment system. Inside, the driving experience is complete with a jet wing-inspired console, panoramic sunroof, and a mix of premium woven and leather fabrics. In an official statement, Tom Lee, Managing Director of MG Motor shared, 'The new MG ZS delivers exactly what today's drivers seek—style, capability, and outstanding value. This latest generation reflects MG's commitment to innovation, not only through upgraded technology but also as part of our broader vision to integrate new EV technologies into our global lineup. We are excited to bring this model to our customers across the region, offering a dynamic and future-ready driving experience.' Take a closer look at the latest MG ZS in the gallery above. To find out more, head to MG Motor'swebsitenow.
